Sildenafil citrate linked to increased chorodial thickness

Article

phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness ? an associated risk factor for central serous chorioretinopathy

A study published in Retina shows the phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness – an associated risk factor for central serous chorioretinopathy.

Dr Susham K. Vance et al., LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, USA, conducted a prospective, interventional study involving the administration of 100 mg of sildenafil citrate to 8 subjects with no previous ocular history. Enhanced depth imaging spectral-domain optical coherence tomography was used to measure choroidal thickness in both eyes at 1-hour and 3-hour intervals after ingestion.

The findings demonstrated that the mean chorodial thickness had increased by 12.3% from 334 μm to 375 μm after 1-hour. The mean choroidal thickness was 11.6% thicker than baseline at the 3-hour interval. No significant changes were noted in choroidal thickness between the 1-hour and 3-hour intervals.

The results were related to previous studies of phosphodiesterase-5 inhibitors and central serous chorioretinopathy. Sildenafil citrate increases choroidal thickness both 1-hour and 3-hours after administration.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.